Share

May 2017; 4 (3) EditorialOpen Access

Foveal thinning in neuromyelitis optica

A sign of retinal astrocytopathy?

Takashi Yamamura, Ichiro Nakashima
First published April 11, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000347
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
437

Share

Article Information

vol. 4 no. 3 e347
DOI: 
https://doi.org/10.1212/NXI.0000000000000347
PubMed: 
28439528
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • First Published April 11, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Takashi Yamamura, MD, PhD and
    2. Ichiro Nakashima, MD, PhD
  1. Takashi Yamamura, MD, PhD and
    2. Scientific Advisory Boards:

    1. (1)Biogen Japan (2) Chugai Pharmaceutical Co., Ltd (3) Takeda Pharamaceutical Co.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Novartis Pharma (2) Nihon Pharmaceutical Co., Ltd., (3) Santen Pharmaceutical Co., Ltd., (4) Abbott Japan Co., Ltd./Eisai Co., Ltd., (5) Biogen Japan, (6) Dainippon Sumitomo Pharma Co., Ltd., (7) Bayer Holding Ltd., (8) Astellas Pharma Inc. (9) Takeda Pharamaceutical Co.

    Editorial Boards:

    1. Clinical and Experimental Neuroimmunology, Editor, since 2010

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Ono Pharmaceutical Co., Ltd., (2) Chugai Pharmaceutical Co., Ltd., (3) Teva Pharmaceutical K.K., (4) Mitsubishi Tanabe Pharma Corporation, (5) Asahi Kasei Kuraray Medical CO., Ltd.

    Research Support, Government Entities:

    1. (1) Ministry of Health, Labour and Welfare of Japan, the Health and Labour Sciences Research Grants on Intractable Diseases (Neuroimmunological Diseases), investigator, since 2010.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ichiro Nakashima, MD, PhD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Received funding for a trip and speaks from Mitsubishi Tanabe Pharma (2012-2016) and Novartis Pharma (2012-2015).

    Editorial Boards:

    1. Served as an editorial board member of Multiple Sclerosis International(2010-present).

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received grant support from LSI Medience Corporation (2012-2016).

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the National Institute of Neuroscience (T.Y.), NCNP, Kodaira, Tokyo; and Department of Neurology (I.N.), Tohoku University School of Medicine, Aoba-ku, Sendai, Japan.
  1. Correspondence to Dr. Yamamura: yamamura{at}ncnp.go.jp
View Full Text

Article usage

Article usage: April 2017 to July 2020

AbstractFullPdfSource
Apr 20172311836Highwire
Apr 2017465pmc
May 20171652851Highwire
May 201793435pmc
Jun 20173275Highwire
Jun 201751718pmc
Jul 201716114Highwire
Jul 2017298pmc
Aug 20171185Highwire
Aug 201751820pmc
Sep 20171541Highwire
Sep 201721212pmc
Oct 2017662Highwire
Oct 201752321pmc
Nov 20171221Highwire
Nov 201731212pmc
Dec 2017255Highwire
Jan 2018076Highwire
Feb 2018083Highwire
Mar 20180164Highwire
Apr 2018082Highwire
Apr 2018187pmc
May 20180175Highwire
Jun 20181422Highwire
Jun 2018189pmc
Jul 20180221Highwire
Aug 20184325Highwire
Aug 201811010pmc
Sep 2018074Highwire
Oct 20180282Highwire
Nov 20180233Highwire
Dec 20180654Highwire
Jan 20190454Highwire
Feb 20193575Highwire
Mar 201913510Highwire
Apr 2019297Highwire
May 20192159Highwire
Jun 20192126Highwire
Jul 20192129Highwire
Aug 201942212Highwire
Sep 2019145Highwire
Oct 201941110Highwire
Nov 20193143Highwire
Dec 20195156Highwire
Jan 2020573Highwire
Feb 2020085Highwire
Mar 20205710Highwire
Apr 2020256Highwire
May 20203146Highwire
Jun 20203106Highwire
Jul 20201127Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Alert Me

Advertisement